ValuePickr Forum

Granules India Ltd

(mrai74) #783

Promoters sold 50 lakh shares to a group of reputed investors in a block deal on the stock exchanges, to mobilize about INR 50 Cr. In addition to it, the promoters are also monetizing personal assets worth up to another 50 Cr., which is expected to be complete shortly

The funds raised through these transactions will be used to reduce promoter leverage by up
to Rs 100 Cr. and which will subsequently bring down the Promoters pledged position to
around 30% from current level of 54%.

(Vilas D'Souza) #784

Any idea on the buyers?

(PK) #785


2 Likes
(mrai74) #786

Good to see that management is walking the talk & have reduced the pledge by almost 35% of total promoter pledge. The pledge during start of quarter was above 6 Cr, which has gone down by 2.15 Cr. Pledge has been the major curse for this scrip & investors can fell fresh life with recent developments.

1 Like
(csteja) #787

Any idea what’s the financial status of the companies where promoter group invests after pledging Granule shares

1 Like
(Sunday) #788
2 Likes
(mrai74) #789

Share Holding details ending Q4

https://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=532482&qtrid=101.00

The major changes are KP selling almost 2% to reduce the pledge & big change in FII holding… seems KPs stake was bought by them.

image

1 Like
(mrai74) #790

US FDA Approval for Acetaminophen

a68c07b1-e2cd-4a8c-bf31-117fdd7ee354.pdf (237.2 KB)

(mrai74) #791

Results on expected lines

Granules_result.pdf (562.8 KB)

Granules achieved the growth on back of inherent stability of the molecules in their portfolio combined with their relentless focus on efficient manufacturing. The primary Revenue growth driver for this quarter was US formulation business, which complimented in overall improvement in profitability margins compared with same quarter of the previous financial year.

Owing to the policy offiscal prudence that they adopted, this year witnessed improvement in Debt profile, Working Capital cycle, and culmination of major capex implementation phase. They are geared up to leverage these assets to create value for stakeholders in long term. During the year under review, Granules along with US subsidiary filed 12 ANDAs, 2 DIV/F5 and 2 CEPs which are important indicators of their constant resolve towards accelerated product filling. The other turning point of the year was the launch of their own label product through US subsidiary marking an important landmark in their corporate journey.

Note from results is “Approved the resignation of Mr. K. Ganesh, Chief Financial Officer of the Company with effect from the closing working hours of May 14, 2019 and the Company is in the process of filling the vacancy.”

CFO leaving at this juncture is messy… we need to wait for concall to get more clarity

2 Likes
(reacher) #792

any idea why cfo resigned > with such a short notice (he is being relieved on 14th May) ? some one must ask this in tomorrow con call

(Vilas D'Souza) #793

It’s not a short notice. His last working day is May 14. He would ordinarily be on notice period.

But it’s always good to check on whether his resignation was routine.

(Amit Agarwal) #794

Granules may be rerating candidate.
Nil observation on USFDA Audits validate quality aspects.
Promotors commited to bring down there pledge position.
Capex in tendum to Growth.
New Products filing & approvals.
Granules indicating successful transition from CRAMs to Formulation Player.
Improving in all aspects

3 Likes
(amolk) #795

Yes but the need to reduce debtor level and improve cash flows. Also lot will depend on oil prices. Granules management in the last call had guided for 25% PAT growth for next 2 to 3 years. i.e. estimate PAT of 295 cr in FY20. Can we assume it trade at 15x? If yes then we can see Granules trade at market cap of 4425cr. Upside of 53%?

(Amit Agarwal) #796

APIs Cos are at sweet spot.
On Quality front there is no doubts post successful USFDA Audits.
Granules have adequate Infra, Capex Plan and Products Cycle that may give quality growth on consistent basis.
Management seems more firm & committed than ever before.

#797

Main issue here is pledging and debt. Mgmt has told in last call by FY20 pledging should be gone.

(mrai74) #798

I don’t think management ever committed this. I recall following

(grohal) #799

At some point they should think about generating free cash flow, otherwise valuation will never improve. Currently there is huge Cash burn every year.

1 Like
#800

From Earnings call Q319
image

1 Like
(mrai74) #801

conflicting statement in same Q3 concall

image

(Vilas D'Souza) #802

Did you listen to the Q4 concall? Plz let’s not speculate. Debt to EBITDA, fcf, pledge, capex, roce were all discussed with more clarity.

This time the management achieved what they had promised in 2018 Q4.

Running a growing business isn’t easy, so let’s allow them bandwidth but keep watching closely